April 22, 2024

Symposium: Accelerating Translation from Discovery to Application

Symposium: Accelerating Translation from Discovery to Application

Titel: Accelerating Translation from Discovery to Application

Termin: 6. Mai 2026

Zeit: 9-13 Uhr

Ort: NMI, Markwiesenstraße 55, 72770 Reutlingen

Teilnahme kostenlos

Mehr Informationen und Anmeldung hier: https://www.nmi.de/en/events/symposium-of-the-biodevcenter


Symposium of the Biological Development Center

Accelerating Translation from Discovery to Application

The development of innovative biologicals often stalls at the transition from academic discovery to clinical application.

The Biologicals Development Center, established by NMI and WSIC with EFRE support, aims to address this challenge by providing comprehensive infrastructure and expertise for the design, production, functionalization, and evaluation of biologicals across therapeutic, diagnostic, and biofunctional domains.

This workshop offers insights into scientific, technological, and manufacturing challenges that shape the future of biologicals. The program includes contributions from the project’s steering committee and invited industry partners.

In addition, the current status of the Center will be presented demonstrating how shared analytical capabilities and structured developability approaches can accelerate early biologicals development.

Together, we explore how coordinated resources and cross‑sector collaboration can strengthen regional innovation and enable biologicals to reach real‑world application faster.

register now

Our latest News

discover more
Member2Member: Where expertise meets the community

Member2Member: Where expertise meets the community

Every company in the bioRN network has a story to tell. More importantly, every company has knowledge that can help others move faster, avoid mistakes and spark new collaborations. That is the idea behind bioRN’s Member2Member series. Instead of traditional company presentations, Member2Member opens the doors to our member organisations and puts their expertise centre […]

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp